Christine Bunt
Christine Bunt has served as Chief Executive Officer at Verseau since March 2017. She is a serial entrepreneur, investor, founder, and CEO of life sciences companies. She is a Partner with 20/20 HealthCare Partners, a private global investment group, managing clients in the biotechnology sector.
Prior to joining Verseau, Christine was the CEO and Founder of INTICA Biomedical (personalized medicine/cancer) and of TARIS Biomedical, a Deshpande startup which she cofounded with MIT Professors Michael Cima and Robert Langer. (Allergan acquired TARIS’ pain and inflammation assets in 2014 for $588 million, and Johnson & Johnson acquired TARIS in 2019.)
Christine’s other prior roles include various leadership positions in worldwide commercialization for inflammation, neuroscience, and cardiovascular products at Merck & Co. in Whitehouse Station, N.J., and various R&D, business management, and commercialization functions at Hoffmann-La Roche in Basel, Switzerland. She holds degrees in medical technology and immunochemistry (biochemistry) from the Institute for Hygiene and Infectious Diseases/Medical School of the University of Saarbrücken in Germany.
Christine serves on various boards of Beth Israel Deaconess Medical Center and the Harvard Medical School Initiative for RNA Medicine.